2017
DOI: 10.1111/petr.13101
|View full text |Cite
|
Sign up to set email alerts
|

Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late‐onset primary isolated central nervous system hemophagocytic lymphohistiocytosis

Abstract: Primary isolated CNS presentation of HLH is exceedingly rare and typically associated with significant morbidity and mortality. We describe an adolescent patient with late-onset, primary isolated CNS HLH and a compound heterozygous PRF1 mutation (c50delT (p.L17 fs); c.1229G>C (p.R410P)), not previously reported with this phenotype. He was successfully treated with allogeneic HSCT following a reduced-intensity conditioning regimen, despite a high pre-HSCT comorbidity index. Two years after transplant, he is ali… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 23 publications
0
6
0
Order By: Relevance
“…A number of case reports have pointed out that FHL can also present as a highly variable and non-specific neuroinflammatory disease [10][11][12][13][14][15][16][17][18][19][20][21][22] in the absence of any systemic features of HLH. This different clinical manifestation leads to initial presentation to the neurologist who is less familiar with this rare disease than the hemato-oncologist or immunologist who are usually confronted with FHL patients due to their systemic inflammatory and hematologic manifestations.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A number of case reports have pointed out that FHL can also present as a highly variable and non-specific neuroinflammatory disease [10][11][12][13][14][15][16][17][18][19][20][21][22] in the absence of any systemic features of HLH. This different clinical manifestation leads to initial presentation to the neurologist who is less familiar with this rare disease than the hemato-oncologist or immunologist who are usually confronted with FHL patients due to their systemic inflammatory and hematologic manifestations.…”
Section: Discussionmentioning
confidence: 99%
“…Notably, there are also case reports of isolated CNS disease in FHL patients, occurring in the absence of any systemic disease features, mostly in older patients with hypomorphic mutations [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Reported cases are rare and therefore the spectrum of clinical manifestations, response to therapy and prognosis remain poorly defined.…”
Section: Introductionmentioning
confidence: 99%
“…8 Patients with PRF1 mutations have been reported with isolated CNS inflammation for weeks to months before therapy initiation 1,912 ; 2 such patients underwent HCT. 9,11 These reports raise, but do not answer, the question as to whether isolated chronic CNS inflammation can occur in the absence of systemic HLH findings.…”
mentioning
confidence: 98%
“…In our cohort, we identified four FHL patients with atypical initial presentations, namely, two FHL2 patients with malignancy (P6 and P7), one FHL5 patient with ALPS (P93), and one FHL2 patient with isolated neurological relapse (P14). Particularly, isolated CNS manifestations in FHL can be challenging to diagnose (17,40,41). These findings highlight some of the atypical manifestations in FHL which may delay diagnosis in selected cases.…”
Section: Discussionmentioning
confidence: 98%